Inspire Pharma shares soar 75% on CF data

Shares of Durham, NC-based Inspire Pharmaceuticals took off this morning after researchers announced that a late-stage trial of its cystic fibrosis therapy produced promising results. Patients taking the drug experienced an improvement in lung function during the 24-week study. After hearing the news on denufosol, investors pushed up Inspire's shares by more than 75 percent.

"The data from this Phase 3 trial with denufosol are encouraging for the cystic fibrosis community because it brings us one step closer to a novel treatment that addresses the basic cystic fibrosis defect," Robert J. Beall, CEO of the Cystic Fibrosis Foundation.

- read the report in the Triangle Business Journal